AbbVie addresses hep C cash flow problems

AbbVie Australia has announced the launch of a program to support timely patient access to their Hepatitis C medications VIEKIRA PAK and VIEKIRA PAK-RBV (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets with or without ribavirin) via community pharmacy. The two therapies are now available on the PBS for the treatment of genotype 1 chronic hepatitis C.1-3.